MYDA Advisors’s Moderna MRNA Stock Holding History

MYDA Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,600	Closed	-$3.96M	–	243
2021 Q4	$3.96M	Buy	+15,600	New	+$4.56M	1.06%	25
2021 Q1	–	Sell	-12,000	Closed	-$1.25M	–	316
2020 Q4	$1.25M	Buy	+12,000	New	+$1.21M	0.37%	60

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MYDA Advisors's MRNA Position: Q2 2020 in Review

MYDA Advisors sold out of Moderna (MRNA) in Q2 2020, closing a stake of 35,500 shares — an estimated $1.94M sold.

MYDA Advisors first reported a position in MRNA in Q1 2020 and held it in 1 quarter. The position peaked at $1.06M in Q1 2020. 489 funds tracked by Wall St. Rank hold MRNA as of Q2 2020.

MYDA Advisors reported no remaining Moderna position as of Q2 2020 after selling out during the quarter.
MYDA Advisors sold 35,500 Moderna shares in Q2 2020, an estimated $1.94M.
MYDA Advisors first reported a position in Moderna in Q1 2020 and held it in 1 quarter.
MYDA Advisors's Moderna position peaked at $1.06M in Q1 2020.
489 funds tracked by Wall St. Rank held Moderna as of Q2 2020.

Based on MYDA Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.